L
Lynn M. Schuchter
Researcher at University of Pennsylvania
Publications - 255
Citations - 27393
Lynn M. Schuchter is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 69, co-authored 236 publications receiving 22615 citations. Previous affiliations of Lynn M. Schuchter include Johns Hopkins University & Beth Israel Deaconess Medical Center.
Papers
More filters
Journal Article
Pharmacokinetics of amifostine: effects of dose and method of administration.
TL;DR: The nonlinear pharmacokinetic behavior of amifostine suggests that administration of doses higher than 740 mg/m2 does not increase the amount of drug available due to urinary excretion of the excess parent drug and its metabolites.
Journal ArticleDOI
Er translocation of the mapk pathway drives therapy resistance in BRAF-mutant melanoma
Rani Ojha,Nektaria Maria Leli,Angelique Onorati,Shengfu Piao,Ioannis I. Verginadis,Feven Tameire,Vito W. Rebecca,Cynthia I. Chude,Sengottuvelan Murugan,Colin Fennelly,Estela Noguera-Ortega,Charleen T. Chu,Shujing Liu,Xiaowei Xu,Clemens Krepler,Min Xiao,Wei Xu,Zhi Wei,Dennie T. Frederick,Genevieve M. Boland,Tara C. Mitchell,Giorgos C. Karakousis,Lynn M. Schuchter,Keith T. Flaherty,Gao Zhang,Meenhard Herlyn,Constantinos Koumenis,Ravi K. Amaravadi +27 more
TL;DR: BRAFi + MEKi-induced ER translocation of the MAPK pathway is necessary for ERK reactivation, which drives autophagy, which reconciles two major targeted therapy resistance pathways and identifies druggable targets, whose inhibition would likely enhance the response to BRAFi + MeKi.
Journal ArticleDOI
Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.
Mark C. Mochel,Michael E. Ming,Sotonye Imadojemu,Tara C. Gangadhar,Lynn M. Schuchter,Rosalie Elenitsas,Aimee S. Payne,Emily Y. Chu +7 more
TL;DR: The development of BP and dermatitis herpetiformis in the context of checkpoint inhibitor therapy is consistent with previous investigations supporting the importance of effector and regulatory T cells in the pathogenesis of these diseases.
Journal ArticleDOI
Lymphatic Invasion Is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma
Xiaowei Xu,Lianjun Chen,DuPont Guerry,Peter R. Dawson,Wei-Ting Hwang,P. VanBelle,David E. Elder,Paul J. Zhang,Michael E. Ming,Lynn M. Schuchter,Phyllis A. Gimotty +10 more
TL;DR: Lymphatic invasion in primary cutaneous melanomas is common across the range of tumor thicknesses in primary VGP melanomas and significantly increases the risk of metastasis in patients in clinical stages IB and IIA.
Journal ArticleDOI
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines
Bradley Garman,Ioannis N. Anastopoulos,Clemens Krepler,Patricia Brafford,Katrin Sproesser,Yuchao Jiang,Bradley Wubbenhorst,Ravi K. Amaravadi,Joseph J. Bennett,Marilda Beqiri,David E. Elder,Keith T. Flaherty,Dennie T. Frederick,Tara C. Gangadhar,Michael J. Guarino,Dave S.B. Hoon,Giorgos C. Karakousis,Qin Liu,Nandita Mitra,Nicholas J. Petrelli,Lynn M. Schuchter,Batool Shannan,Carol L. Shields,Jennifer A. Wargo,Brandon Wenz,Melissa Wilson,Min Xiao,Wei Xu,Xaiowei Xu,Xiangfan Yin,Nan Zhang,Michael A. Davies,Meenhard Herlyn,Katherine L. Nathanson +33 more
TL;DR: These well-characterized melanoma PDXs and cell lines can be used not only as reagents for a large array of biological studies but also as pre-clinical models to facilitate drug development.